DIH Holding US (DHAI) Competitors $0.24 +0.02 (+7.02%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$0.37 +0.13 (+54.55%) As of 08/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DHAI vs. PSTV, WOK, MLSS, NMTC, MODD, TMDIF, POCI, PYPD, NEPH, and COCHShould you be buying DIH Holding US stock or one of its competitors? The main competitors of DIH Holding US include Plus Therapeutics (PSTV), WORK Medical Technology Group (WOK), Milestone Scientific (MLSS), NeuroOne Medical Technologies (NMTC), Modular Medical (MODD), Titan Medical (TMDIF), Precision Optics (POCI), PolyPid (PYPD), Nephros (NEPH), and Envoy Medical (COCH). These companies are all part of the "medical equipment" industry. DIH Holding US vs. Its Competitors Plus Therapeutics WORK Medical Technology Group Milestone Scientific NeuroOne Medical Technologies Modular Medical Titan Medical Precision Optics PolyPid Nephros Envoy Medical Plus Therapeutics (NASDAQ:PSTV) and DIH Holding US (NASDAQ:DHAI) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Which has more risk and volatility, PSTV or DHAI? Plus Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, DIH Holding US has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Do institutionals and insiders have more ownership in PSTV or DHAI? 3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 27.8% of DIH Holding US shares are held by institutional investors. 0.8% of Plus Therapeutics shares are held by company insiders. Comparatively, 49.6% of DIH Holding US shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better valuation and earnings, PSTV or DHAI? DIH Holding US has higher revenue and earnings than Plus Therapeutics. DIH Holding US is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus TherapeuticsN/AN/A-$12.98M-$2.24-0.28DIH Holding US$64.47M0.18-$8.44M-$0.30-0.80 Do analysts rate PSTV or DHAI? Plus Therapeutics presently has a consensus price target of $10.83, indicating a potential upside of 1,625.33%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Plus Therapeutics is more favorable than DIH Holding US.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50DIH Holding US 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to PSTV or DHAI? In the previous week, Plus Therapeutics had 15 more articles in the media than DIH Holding US. MarketBeat recorded 17 mentions for Plus Therapeutics and 2 mentions for DIH Holding US. Plus Therapeutics' average media sentiment score of 0.59 beat DIH Holding US's score of 0.41 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Plus Therapeutics Positive DIH Holding US Neutral Is PSTV or DHAI more profitable? DIH Holding US has a net margin of -13.59% compared to Plus Therapeutics' net margin of -357.85%. Company Net Margins Return on Equity Return on Assets Plus Therapeutics-357.85% N/A -123.89% DIH Holding US -13.59%N/A -25.97% SummaryPlus Therapeutics and DIH Holding US tied by winning 7 of the 14 factors compared between the two stocks. Get DIH Holding US News Delivered to You Automatically Sign up to receive the latest news and ratings for DHAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DHAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DHAI vs. The Competition Export to ExcelMetricDIH Holding USTechnology Services IndustryBusiness SectorNASDAQ ExchangeMarket Cap$10.59M$2.62B$22.10B$9.82BDividend YieldN/A1.55%2.82%4.07%P/E Ratio-0.8022.6527.4725.12Price / Sales0.1836.5540.96115.60Price / CashN/A45.4127.1059.05Price / Book-0.306.255.636.18Net Income-$8.44M$33.68M$198.39M$264.89M7 Day Performance-11.00%0.34%0.82%4.18%1 Month Performance3.37%-4.42%-1.82%1.99%1 Year Performance-90.39%37.62%29.06%24.22% DIH Holding US Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DHAIDIH Holding US0.6237 of 5 stars$0.24+7.0%N/A-90.1%$10.59M$64.47M-0.80N/AShort Interest ↑High Trading VolumePSTVPlus Therapeutics2.8261 of 5 stars$0.66-11.0%$10.83+1,546.4%-55.2%$44.71M$5.82M-0.2220News CoverageEarnings ReportAnalyst UpgradeShort Interest ↓Analyst RevisionGap UpHigh Trading VolumeWOKWORK Medical Technology GroupN/A$0.80+3.9%N/AN/A$43.42M$11.51M0.00226Positive NewsGap DownMLSSMilestone Scientific2.3725 of 5 stars$0.53-3.8%$1.25+136.3%-33.7%$41.51M$8.61M-7.5630News CoverageShort Interest ↑High Trading VolumeNMTCNeuroOne Medical Technologies2.714 of 5 stars$0.81-1.5%$1.45+78.8%+12.3%$41M$3.45M-3.6920Trending NewsEarnings ReportMODDModular Medical0.8229 of 5 stars$0.71-4.6%N/A-57.4%$40.09MN/A-1.3820Earnings ReportHigh Trading VolumeTMDIFTitan MedicalN/A$0.33-7.1%N/A+920.5%$37.07M$17.63M-0.2650Gap DownPOCIPrecision Optics0.7593 of 5 stars$4.66-2.1%N/A-11.0%$36.47M$19.10M-5.2480Gap DownPYPDPolyPid3.0229 of 5 stars$3.37-2.0%$11.80+250.1%-4.4%$35.06MN/A-0.7880News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionGap DownNEPHNephros2.4473 of 5 stars$3.10-4.3%$5.00+61.3%+127.3%$34.35M$14.16M44.2930Positive NewsHigh Trading VolumeCOCHEnvoy Medical3.4746 of 5 stars$1.48+3.5%$9.25+525.0%-45.2%$30.50M$220K-1.0334Negative News Related Companies and Tools Related Companies Plus Therapeutics Alternatives WORK Medical Technology Group Alternatives Milestone Scientific Alternatives NeuroOne Medical Technologies Alternatives Modular Medical Alternatives Titan Medical Alternatives Precision Optics Alternatives PolyPid Alternatives Nephros Alternatives Envoy Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DHAI) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIH Holding US, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DIH Holding US With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access